Short Interest in Mainz Biomed (NASDAQ:MYNZ) Drops By 21.6%

Mainz Biomed (NASDAQ:MYNZ) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 79,700 shares, a drop of 21.6% from the February 13th total of 101,700 shares. Based on an average daily volume of 208,300 shares, the days-to-cover ratio is currently 0.4 days. Approximately 3.8% of the company’s shares are short sold.

Mainz Biomed Trading Up 6.2 %

NASDAQ:MYNZ traded up $0.27 during mid-day trading on Monday, hitting $4.63. The company had a trading volume of 93,253 shares, compared to its average volume of 90,018. The business has a fifty day simple moving average of $5.47 and a 200-day simple moving average of $8.00. Mainz Biomed has a 1 year low of $3.65 and a 1 year high of $45.20. The firm has a market capitalization of $9.26 million, a price-to-earnings ratio of -0.07 and a beta of 0.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC bought a new stake in shares of Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed at the end of the most recent reporting period.

Analysts Set New Price Targets

Several research firms have recently issued reports on MYNZ. HC Wainwright cut Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday, November 25th. Maxim Group began coverage on Mainz Biomed in a research report on Friday, February 14th. They issued a “buy” rating and a $14.00 target price on the stock.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.